TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00577070

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
Study: NCT01375413

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: Physical therapy consisting of gait training 3 times a week for 6 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Physical therapy consisting of gait training 3 times a week for 6 weeks
Study: NCT03416010

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COPE-P
Description: Session 1 ABCs (A=Antecedent or Activator event, B=Belief that follows the event, C=Consequence: how you feel and how you behave).~Session 2 self-esteem and positive self-talk, including ways to build self-esteem and the group provides examples of how to change unhealthy habits into healthy ones.~Session 3 stress/coping during pregnancy. Physical and emotional responses to stress are discussed along with healthy snacking and healthy ways to cope with typical stresses.~Session 4 planning, goal setting and the 4-step problem solving process. Session 5 dealing with emotions in healthy ways through positive thinking and effective communication.~Session 6 coping with stressful situations encountered during pregnancy while continuing to reinforce the thinking-feeling-behaving triangle.
Study: NCT00910377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling sessions
Description: The intervention groups received counseling sessions about breastfeeding and complementary feeding at maternity ward and at home with 7,15,30,60 and 120 days.
Study: NCT01344694

Intervention type: OTHER
Intervention: patient with liver fat
Description: 30 patient with liver fat

Intervention type: OTHER
Intervention: pts. with excess of visceral fat
Description: pts. with excess of visceral fat

Intervention type: OTHER
Intervention: control
Description: 30 control subjects
Study: NCT02417558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alterniity Augmented Reality (AAR)
Description: AAR is a patent pending exercise and gaming (exergaming) computer platform with a physical training component (PTC) and a cognitive training component (CTC). It fully immerses a user inside a virtual environment where he is practising complex everyday activities, such as going shopping, using the transportation, visiting a foreign city, eating at a restaurant, cooking dinner etc. His motor behaviour is monitored by means of motion capture, while immersed at this full-body immersion. In addition his cognition is monitored in real-time with Personalized Brain Network Activity (PBNA) screening. Both the motor and brain analyses are then used to update the configuration, type and difficulty of the AAR scenarios.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VideoGrade
Description: Active cognitive training by use of the VideoGrade software by Aristotle University of Thessaloniki.
Study: NCT03282422

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based protocol in specific tasks
Description: The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based protocol in specific tasks
Description: The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper-limb splint
Description: In the case that treatment with splint is also received, a researcher of this study will take measurements of the hand and will provide the appropriate splint. The intensity of the application will be 5 days a week from monday to friday, for 6 hours a day, for a period of 6 weeks.
Study: NCT03644420

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical evaluation
Description: Functional scores for the pathological joint will be determined

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiology
Study: NCT04144712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate
Description: study rate of occurrence of Apnea of Prematurity between the 2 groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Citrate
Description: study rate of occurrence of Apnea of Prematurity between the 2 groups
Study: NCT02808975

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections administered as described in arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous injections administered as described in arm description
Study: NCT00132678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal Consta
Description: 12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo intramuscular (IM) injection every 2 weeks
Study: NCT03318029

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation
Description: Vitamin D supplementation of 600 IU daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation
Description: Vitamin D supplementation of 600 IU daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: rice flour with no vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: rice flour with no vitamin D
Study: NCT01081847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptides (N,R&C) formulated in Montanide ISA 720
Description: 50 ug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptides (N,R&C) formulated in Montanide ISA 51
Description: 50 ug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptides (N,R&C) formulated in Montanide ISA 720
Description: 100 ug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptides (N,R&C) formulated in Montanide ISA 51
Description: 100 ug
Study: NCT03644420

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic contrast-enhanced magnetic resonance imaging
Description: Patients will be examined using a 3T MR scanner (MR 750W, General Electrics, Milwaukee, WI) with a dedicated knee coil. Subchondral bone marrow vascularization in medial and lateral femorotibial compartments will be assessed with DCE-MRI and lesions will be graded on MR images.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of histological status
Description: Upper tibial resection pieces will be collected and the vascularization will be determined according to the OARSI score
Study: NCT03403452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
Study: NCT01081847

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLacebo: Isotonic saline solution
Study: NCT04640441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-to-stand care
Description: 1. Passive range of motion(ROM) exercise of lower legs, active ROM exercise of lower legs, and sitting balance exercise, 20\~30 min, once daily.~2. Anti-gravity ROM exercise of lower leg, resistance exercise of low leg, and sitting balance exercise, 20\~30min, once daily.~3. Stepping exercise and sit-to-stand exercise, 20\~30min, once daily.
Study: NCT00463814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Participants will receive single oral dose of AZD6244 as described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Participants will receive single oral dose of AZD6244 as described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Participants will receive single oral dose of AZD6244 as described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Participants will receive single oral dose of AZD6244 as described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Participants will receive single oral dose of AZD6244 as described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Participants will receive single oral dose of AZD6244 as described in arm description.
Study: NCT05691777

Intervention type: DEVICE
Intervention: Hand and shoulder task
Description: Hand task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform flexion / extension movements of the fingers of the right hand at 0.5 Hz.~Shoulder task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform alternating movement of abduction and adduction of the right shoulder at 0.5 Hz with the elbow flexed.
Study: NCT03206840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control, meditation, hypnosis.
Description: three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control, meditation, hypnosis.
Description: three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects.
Study: NCT01054222

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
Study: NCT04194047

Intervention type: OTHER
Intervention: Transfusion
Description: RBC transfusion (1 unit)

Intervention type: OTHER
Intervention: Crystalloids infusion
Description: Infusion of 500 ml of balanced crystalloids
Study: NCT04023214

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral (digital) arterial tonometry
Description: This will be measured using the EndoPAT system (Itamar Medical)

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral (digital) arterial tonometry
Description: This will be measured using the EndoPAT system (Itamar Medical)
Study: NCT00696319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol with perturbation exercises.
Description: Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol with traditional exercises for stability and balance.
Description: The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
Study: NCT00193739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NACT
Description: 3 cycles of neoadjuvant chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling
Description: NACT followed by surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inj.Cisplatin
Description: Concurrent chemo radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemo radiotherapy
Description: Radiation therapy will be administered to the whole pelvis region followed by intracavitary brachytherapy.
Study: NCT04168320

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)
Description: Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
Study: NCT03768336

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control
Description: The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being. Waitlist control receives the adapted 3RP program (3RP-AYA) approximately 2 months after study enrollment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3RP-AYA
Description: The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being.
Study: NCT04168320

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)
Description: Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
Study: NCT02865629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
Study: NCT01605825

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/dalfampridine-ER
Description: Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalfampridine-ER/placebo
Description: Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
Study: NCT04053439

Intervention type: OTHER
Intervention: Blood test for determination of CHIP
Description: Patients will have one additional blood draw to be sent for DNA extraction and sequencing for CHIP.
Study: NCT03659162

Intervention type: DRUG
Intervention: Azole Antifungal
Description: oral gel \& injections
Study: NCT03743779

Intervention type: BEHAVIORAL
Intervention: Mastering Diabetes
Description: The Mastering Diabetes provides a step-by-step program to transition to a low-fat, plant-based, whole-food lifestyle and reduce overwhelm. The program also provides direct access to expert coaches in the online community, which contains others living with all forms of diabetes. I includes access to live Q\&A videoconferences twice per month to interact with coaches and personalize the experience.~The program is designed with seven core modules. Many participants continue in the program after completion of the modules for ongoing support.~The cost was $29/month or $249/year, but as of July 2018, only the $249/year option is offered.
Study: NCT02571088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Program
Description: Each training session will last 45 min. Exercise will start by a 5-min warm-up cycling period, followed by 30 min of cycling at the power output (W) individually determined before and corresponding to the first lactate threshold corresponding approximately to 2.5 mmol/l . Then patients will cool down for 5 min. Finally, the training sessions will end by 5 min of light stretching. All training sessions will take place at the hospital and will be under the supervision of a physician. Heart rate, oxygen saturation and blood lactate concentrations will be regularly measured. Work rate will be adjusted according to the obtained results. As a safety procedure, blood lactate concentration must not exceed 4 mmol/L during the training sessions. A particular attention will be paid to the hydration of patients. Pain and fatigue will be evaluated everyday by the patients using (100 mm) visual analog scales.
Study: NCT02980042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: A humanized monoclonal antibody that targets CD20 and selectively depleted CD-20 expressing B cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: A chimeric monoclonal antibody against CD20.
Study: NCT03798275

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coffee
Description: 2 g Nescafe Clasico contains approximately 65 mg caffeine
Study: NCT01135654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment
Description: We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to Helping Patients Who Drink Too Much.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment
Description: We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to Helping Patients Who Drink Too Much.
Study: NCT03503929

Intervention type: DEVICE
Group type: OTHER
Intervention: LaparoGuard System
Description: Adjunctive safety system for laparoscopic surgery
Study: NCT03289559

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GnRH antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aromatase Inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Study: NCT03591484

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Treatment with Photodynamic therapy. The evaluation of halitosis and the microbiological analysis will be repeated before this step

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Treatment with Photodynamic therapy. The evaluation of halitosis and the microbiological analysis will be repeated before this step

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with tongue scraper
Description: Treatment with tongue scraper. The evaluation of halitosis and the microbiological analysis will be repeated before this step

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with tongue scraper
Description: Treatment with tongue scraper. The evaluation of halitosis and the microbiological analysis will be repeated before this step

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: Periodontal treatment will be performed with curettes and ultrassom. The evaluation of halitosis and the microbiological analysis will be repeated before this step

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal treatment
Description: Periodontal treatment will be performed with curettes and ultrassom. The evaluation of halitosis and the microbiological analysis will be repeated before this step

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hygiene procedures for the mucosa and dentures
Description: edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before this step

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hygiene procedures for the mucosa and dentures
Description: edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before this step
Study: NCT01400360

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Combination of TBA and intraarterial application of vasodilators
Description: In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination of TBA and intraarterial application of vasodilators
Description: In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.
Study: NCT03546153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Description: Exercise program consists of training for 60 minutes, three times per week for 12 weeks. Participants will use a treadmill, Nu stepper/bike or elliptical to exercise.
Study: NCT00664963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of YUKON Sirolimus-eluting Stent
Description: Implantation of YUKON Sirolimus-eluting Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of YUKON Stent (uncoated)
Description: Implantation of YUKON Stent (uncoated)